STAT+: Pharmalittle: We’re reading about a Vera kidney drug approval, a U.K. Enhertu pricing deal, and more

STAT PlusNewsletterPharmalot Pharmalittle: We’re reading about a Vera kidney drug approval, a U.K. Enhertu pricing deal, and more Hong Kong-based Sino Biopharm strikes a pair of deals for respiratory drugs Manage alerts for this article Email this article Share this article By Jason MastJuly 8, 2026 General Assignment Reporter Jason Mast[email protected]Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Good morning, Jason Mast here filling in for the one and only Ed Silverman. We’re here in STAT’s Brooklyn outpost today, where everyone’s gazing across the East River to see whether Pfizer’s former headquarters will — quite literally, quite alarmingly — crumble to the ground. It does appear things are more stable than yesterday, which will hopefully give us time and the breathing space to focus on today’s headlines. … The FDA approved a new kidney disease drug from Vera Therapeutics, STAT states. The drug, called Trutakna, is designed to treat IgA nephropathy, a condition in which immune antibodies build up in the kidneys. It is one of several drugs now entering or nearing the market for the disease. Vera will charge $425,000 annually before customary insurance discounts and rebates.Advertisement U.K. officials are nearing a drug-pricing deal with AstraZeneca and Daiichi Sankyo to assure access to a life-extending breast cancer drug, Bloomberg reports. The deal would allow certain women in England and Wales to receive Enhertu, an antibody-drug conjugate that has been shown to extend survival for some patients by around six months and is widely available elsewhere. The U.K. drug-pricing regulator had previously deemed the medicine not cost-effective — though that was before the U.K. changed some of its drug-pricing metrics as part of a trade deal with the Trump administration. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In pharmalittle, STAT+ Submit a correction requestReprints Jason Mast General Assignment Reporter Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Newsletter Understand how science, health policy, and medicine shape the world every day Recommended Pharmalot July 7, 2026 STAT Plus: Pharmalittle: We’re reading about a $10 billion Vertex deal, the pace of FDA drug approvals, and more Pharmalot July 6, 2026 STAT Plus: Pharmalittle: We’re reading about a Novartis acquisition, Republicans backing clinical trial diversity, and more Advertisement Pharmalot July 2, 2026 STAT Plus: Lawmakers urge HHS to force Eli Lilly to provide 340B drug discounts to hospitals Pharmalot July 2, 2026 STAT Plus: Up and down the ladder: The latest comings and goings Pharmalot July 2, 2026 STAT Plus: Pharmalittle: We’re reading about a court win for Amgen, Novo seeking supplier discounts, and more Subscriber Picks